HK1162667A1 - Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy - Google Patents

Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy

Info

Publication number
HK1162667A1
HK1162667A1 HK12102802.0A HK12102802A HK1162667A1 HK 1162667 A1 HK1162667 A1 HK 1162667A1 HK 12102802 A HK12102802 A HK 12102802A HK 1162667 A1 HK1162667 A1 HK 1162667A1
Authority
HK
Hong Kong
Prior art keywords
nucleolin
endostatin
kit
likelihood
success
Prior art date
Application number
HK12102802.0A
Other languages
English (en)
Chinese (zh)
Inventor
羅永章
石虎兵
張卓兵
Original Assignee
清華大學
北京普羅吉生物科技發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 清華大學, 北京普羅吉生物科技發展有限公司 filed Critical 清華大學
Publication of HK1162667A1 publication Critical patent/HK1162667A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HK12102802.0A 2005-05-12 2012-03-20 Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy HK1162667A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2005100117073A CN1862258B (zh) 2005-05-12 2005-05-12 核仁素辅助的癌症诊断与治疗方法

Publications (1)

Publication Number Publication Date
HK1162667A1 true HK1162667A1 (en) 2012-09-21

Family

ID=37389730

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08110478.2A HK1114903A1 (en) 2005-05-12 2008-09-22 Auxiliary method for diagnosis and therapy of cancer with nucleolin
HK12102802.0A HK1162667A1 (en) 2005-05-12 2012-03-20 Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK08110478.2A HK1114903A1 (en) 2005-05-12 2008-09-22 Auxiliary method for diagnosis and therapy of cancer with nucleolin

Country Status (11)

Country Link
US (3) US20060258605A1 (xx)
EP (2) EP1912066B1 (xx)
JP (3) JP4742142B2 (xx)
CN (2) CN102539734B (xx)
AT (1) ATE516499T1 (xx)
AU (2) AU2006246197B2 (xx)
CA (1) CA2607832A1 (xx)
DK (1) DK1912066T3 (xx)
ES (2) ES2538344T3 (xx)
HK (2) HK1114903A1 (xx)
WO (1) WO2006119706A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN102539734B (zh) 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
US20090226914A1 (en) * 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
CN102770529B (zh) * 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011123945A1 (en) * 2010-04-06 2011-10-13 The University Of British Columbia Compostions, methods and uses for treating respiratory syncytial virus infection
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
US20130023479A1 (en) * 2011-07-22 2013-01-24 Protgen Ltd. Use of nucleolin as a biomarker for lymphangiogenesis in cancer prognosis and therapy
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
WO2017011411A1 (en) * 2015-07-10 2017-01-19 Ohio State Innovation Foundation Methods and compositions relating to anti-nucleolin recombinant immunoagents
CN106405096A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备胃癌诊断试剂和治疗药物中的应用
CN106405084A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备肠癌诊断试剂和治疗药物中的应用
WO2017181049A1 (en) * 2016-04-15 2017-10-19 Charlestonpharma, Llc Anti-nucleolin agents
CN116754768B (zh) * 2023-05-30 2024-03-29 中山大学附属第五医院 Ddx24在维持内皮细胞的核仁稳态中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
CN1266064A (zh) * 1999-03-03 2000-09-13 华西医科大学 血管生成抑制因子—内皮抑素及其制备方法
JP2003180368A (ja) 2001-12-19 2003-07-02 Pharma Design Inc 癌患者に対する放射線治療の有効性の予測方法
WO2003087124A2 (en) * 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
EP2060918A3 (en) * 2003-04-01 2009-08-26 The Johns Hopkins University Breast endothelial cell expression patterns
CA2526036A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
CN102539734B (zh) 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法

Also Published As

Publication number Publication date
ES2369383T3 (es) 2011-11-30
ES2538344T3 (es) 2015-06-19
AU2006246197B2 (en) 2010-08-19
ATE516499T1 (de) 2011-07-15
JP4742142B2 (ja) 2011-08-10
EP2375251B1 (en) 2015-04-08
EP1912066A1 (en) 2008-04-16
EP1912066A4 (en) 2008-10-15
US20060258605A1 (en) 2006-11-16
US11434288B2 (en) 2022-09-06
AU2006246197A1 (en) 2006-11-16
JP2011013225A (ja) 2011-01-20
EP1912066B1 (en) 2011-07-13
JP5758962B2 (ja) 2015-08-05
US20230174644A1 (en) 2023-06-08
AU2010241351A1 (en) 2010-12-02
HK1114903A1 (en) 2008-11-14
CN102539734B (zh) 2016-02-03
CN1862258B (zh) 2012-05-30
JP2008541066A (ja) 2008-11-20
CN1862258A (zh) 2006-11-15
JP5502652B2 (ja) 2014-05-28
JP2014032203A (ja) 2014-02-20
AU2010241351B2 (en) 2013-04-04
CN102539734A (zh) 2012-07-04
DK1912066T3 (da) 2011-10-24
US20090191224A1 (en) 2009-07-30
EP2375251A1 (en) 2011-10-12
CA2607832A1 (en) 2006-11-16
WO2006119706A1 (fr) 2006-11-16

Similar Documents

Publication Publication Date Title
HK1162667A1 (en) Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy
ATE450547T1 (de) Eml4-alk-fusionsgen
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
EP1961827A3 (en) Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
WO2005093094A3 (en) Methods and means for nucleic acid sequencing
WO2005118876A3 (en) Egfr mutations
PH12012500758A1 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
TW200745556A (en) Biomarkers for liver fibrotic injury
WO2009015294A8 (en) Biomarkers for human papillomavirus-associated cancers
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
ATE491809T1 (de) Amplifikation von dna-fragmenten
WO2009097511A3 (en) Two stage enrichment of cell-free fetal dna in maternal plasma
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2005084277A3 (en) Method of isolating nucleic acid targets
WO2008063655A3 (en) Dna methylation markers and methods of use
WO2007002746A3 (en) Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
CN100557031C (zh) 检测基质金属蛋白酶活性的多核苷酸序列
WO2004074441A3 (en) Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200518